Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety/Efficacy of Intranasally-Administered Bioactive Factors Produced by M2 Type Macrophages in Children With Developmental Speech Disorders

NCT04689282 is registered in ClinicalTrials.gov with Russian Academy of Medical Sciences as lead sponsor.

NCT NCT04689282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04689282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety/Efficacy of Intranasally-Administered Bioactive Factors Produced by M2 Type Macrophages in Children With Developmental Speech Disorders
Lead sponsor
Russian Academy of Medical Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2020
Completion date
September 1, 2021
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit-hyperactivity disorder, autism spectrum disorder, language delay, language; developmental disorder, expressive, language; developmental disorder, receptive, speech disorders in children